Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lucitanib
- Development stage
- Phase 3
- Lead developer
- Advenchen Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lucitanib is a small molecule multi-targeted tyrosine kinase inhibitor that blocks the activity of vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors alpha and beta (PDGFRα/β). It inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR2 in the nanomolar range. This inhibition results in suppression of tumor angiogenesis and tumor cell proliferation and can induce tumor cell death. Lucitanib is being investigated for the treatment of advanced solid tumors including metastatic breast cancer and gynecological malignancies. It is administered orally[1][3][5].
- Brand names
- Lucitanib
- Other names
- 6-((7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-N-methyl-1-naphthamide
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR1 (Fibroblast growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on lucitanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lucitanib.